Document is current
Any future updates will be listed below
-
Authors
Ginès, Pere https://orcid.org/0000-0003-4657-4504
Thiele, Maja https://orcid.org/0000-0003-1854-1924
Graupera, Isabel
Serra-Burriel, Miquel
de Knegt, Robert J.
Lammert, Frank
Castera, Laurent
Korenjak, Marko https://orcid.org/0000-0003-4024-677X
Kamath, Patrick S. https://orcid.org/0000-0002-7888-1165
Grgurević, Ivica
Piano, Salvatore
Fabrellas, Núria
Arslanow, Anita
Krag, Aleksander https://orcid.org/0000-0002-9598-4932
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (847989)
- License Information
-
More Information
Article History
First Online: 31 March 2023
Competing interests
: P.G. has received research funding from Gilead, Mallinckrodt, Grifols and Ferring; consulting fees from Grifols SA, Ferring Pharmaceuticals, Gilead, Intercept, Martin Pharmaceuticals, Promethera, Sequana, RallyBio and Behring. M.T. has been funded by a grant from the Novo Nordisk Foundation (DECIDE project, grant no. NNF20OC0059393), and received speaker’s fee from Echesens, Siemens Healthcare, Norgine and Tillotts Pharma and an advisory fee from GE Healthcare. R.J.dK. has received honoraria for consulting or speaking in the past 5 years from AbbVie, BMS, Echosens, Gilead, Jansen-Cilag and Norgine; fees for contract research for current trials from Echosens, GSK, Inventiva-Pharma and Jansen-Cilag; and research grants from Gilead. L.C. has received a research grant from Gilead; consulting fees from Echosens, Madrigal, MSD, Novo Nordisk, Pfizer and Sagimet; and lecture fees from Echosens and Novo Nordisk. I. Grgurević has received speaker fees from Echosens, Siemens and Roche and holds an advisory board position at General Electric. S.P. has received consulting fees from Plasma Protein Therapeutics Association and Resolution therapeutics. N.F. has received consulting fees from Intercept. All other authors report no competing interests.
